SEC Filing Summary: Spherix Incorporated (Form 10-K)
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2002, for Spherix Incorporated (formerly Biospherics Incorporated). The Company operates two primary segments: InfoSpherix, an information services division providing government and commercial data management, and BioSpherix, a biotechnology division focused on the development of tagatose (a low-calorie sweetener) and safe-for-humans pesticides. The Company is headquartered in Beltsville, Maryland.
Key Financial Metrics
| Metric | 2002 | 2001 |
|---|---|---|
| Total Revenue | $15,132,000 | $19,937,000 |
| Net (Loss) Income | $(2,922,000) | $568,000 |
| Net (Loss) Income Per Share (Diluted) | $(0.26) | $0.05 |
| Total Assets | $15,453,000 | $13,241,000 |
| Working Capital | $8,788,000 | $7,139,000 |
| Cash and Cash Equivalents | $8,656,000 | $6,582,000 |
| Long-Term Debt | $91,000 | $104,000 |
| Bank Line of Credit (Outstanding) | $722,000 | $213,000 |
Segment Performance: InfoSpherix generated $15.04 million in revenue (99% of total), while BioSpherix generated $89,000 (1% of total). InfoSpherix reported an operating loss of $1.24 million in 2002, compared to a profit of $1.11 million in 2001.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 24% ($4.8 million) compared to 2001. This was driven primarily by a 78% drop in commercial contract revenue within the InfoSpherix segment, attributed to the expiration of a significant short-term pharmaceutical contract in 2001.
- Net Loss: The Company swung from a net income of $568,000 in 2001 to a net loss of $2.92 million in 2002. This was caused by reduced revenue and increased Selling, General, and Administrative (SG&A) expenses, largely due to legal fees associated with arbitration against licensee Arla Foods.
- Government Contract Concentration: The National Park Service (NPS) contract accounted for 27% of total revenue in 2002. In December 2002, the NPS notified the Company of the cancellation of the procurement for the National Park Reservation System, though the Company is contesting this action.
- Liquidity Improvement: Despite the operating loss, working capital increased by $1.65 million, primarily due to $3.7 million in proceeds from the exercise of stock warrants by an institutional investor.
Guidance, Outlook, Risks, and Contingencies
- Arbitration with Arla Foods: Spherix filed for arbitration in May 2002 against its tagatose licensee, Arla Foods, citing delays in commercialization. Spherix seeks monetary damages and potential recovery of licensed rights. The Company has incurred approximately $473,000 in legal fees to date and expects significant additional expenses in 2003.
- Tagatose Commercialization: Arla plans to begin commercial production of tagatose in April or May 2003. Spherix retains rights to non-food uses (branded as "Naturlose") and is pursuing independent production and sales for pharmaceutical and cosmetic applications.
- Government Contract Risks: The Company is contesting the NPS contract cancellation. Additionally, revenue is heavily concentrated in government contracts (94% of InfoSpherix revenue), which are subject to termination at the government's convenience.
- Capital Resources: The Company has a $2 million line of credit with Bank of America, with $1.07 million available as of year-end. Management believes current cash reserves and the line of credit are sufficient to meet obligations for 2003, even if the credit line is not renewed.
- Outlook: The Company expects revenue from the U.S. Government, State of Michigan, and State of Maryland to each account for more than 10% of total revenues in 2003. No dividends are anticipated.
Key Facts for Investor Verification
- Arbitration Outcome: Verify the status and potential financial impact of the ongoing arbitration against Arla Foods regarding tagatose commercialization delays.
- NPS Contract Status: Confirm the resolution of the National Park Service contract cancellation dispute and its impact on future revenue streams.
- Commercial Revenue Recovery: Assess the Company's ability to replace the lost commercial pharmaceutical contracts that drove revenue in 2001.
- Tagatose Royalties: Monitor the timeline for Arla's commercial production of tagatose, as this is the primary source of future royalty revenue for the BioSpherix segment.
- Debt Covenants: Review compliance with the tangible net worth ratios required by the Bank of America credit agreement.